Integrated Filing — IndAS



General information about company

Scrip Code 539523
NSE Symbol ALKEM
MSEI Symbol NOTLISTED
ISIN INE540L01014
Name of company ALKEM LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 12-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-11-2026   11:30:00
End date and time of board meeting 12-11-2026   13:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 4,55,199.00 8,29,214.00
Other income 13,421.00 28,696.00
Total income 4,68,620.00 8,57,910.00
2 Expenses
(a) Cost of materials consumed 1,08,303.00 1,99,305.00
(b) Purchases of stock-in-trade 46,883.00 83,482.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (5,711.00) (13,185.00)
(d) Employee benefit expense 89,652.00 1,70,542.00
(e) Finance costs 5,767.00 10,429.00
(f) Depreciation, depletion and amortisation expense 13,708.00 23,727.00
(f) Other Expenses
1 Other Expenses 1,13,553.00 2,09,946.00
Total other expenses 1,13,553.00 2,09,946.00
Total expenses 3,72,155.00 6,84,246.00
3 Total profit before exceptional items and tax 96,465.00 1,73,664.00
4 Exceptional items 3,500.00 3,500.00
5 Total profit before tax 99,965.00 1,77,164.00
6 Tax expense
7 Current tax 40,534.00 63,740.00
8 Deferred tax (7,343.00) (5,499.00)
9 Total tax expenses 33,191.00 58,241.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 66,774.00 1,18,923.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method (61.00) (112.00)
16 Total profit (loss) for period 66,713.00 1,18,811.00
17 Other comprehensive income net of taxes (1,159.00) (871.00)
18 Total Comprehensive Income for the period 65,554.00 1,17,940.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 67,534.00 1,19,530.00
Total profit or loss, attributable to non-controlling interests (821.00) (719.00)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 66,764.00 1,19,050.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests (1,210.00) (1,110.00)
21 Details of equity share capital
Paid-up equity share capital 2,391.00 2,391.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 56.48 99.97
Diluted earnings (loss) per share from continuing operations 56.48 99.97
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 56.48 99.97
Diluted earnings (loss) per share from continuing and discontinued operations 56.48 99.97
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2. The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 November 2026 and subsequently approved by the Board of Directors at its meeting held on 12 November 2026. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2026. 3. Exceptional item includes: a) Exceptional item for the quarter and six months ended 30 September 2026 represents recovery of Rs. 350 million against investment made, which was impaired during the quarter and year ended 31 March 2026. b) Exceptional item amounting to Rs.142.9 million for the six months ended 30 September 2025 is on account of gain on sale of Indore facility which was impaired earlier. c) Exceptional items amounting to Rs.1,748.3 million for the year ended 31 March 2026 mainly includes - Impact of labour code of Rs. 1,130.6 million towards gratuity and leave encashment for past service cost; - Impairment of real estate investment made of Rs.747 million; - Gain on sale of Indore facility of Rs.142.9 million. 4. During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; had decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate for the year ended 31 March 2026. Subsequently in the current period, the tax expense has been recognized based on the enacted tax rates applicable under the new regime. 5. During the quarter ended 30 September 2026, Alkem Medtech Private Limited (AMPL), a wholly owned subsidiary of the Parent Company, completed the acquisition of a 55% equity stake in Occlutech Holding AG (Occlutech) pursuant to the Share Purchase Agreement (SPA). The acquisition of controlling interest was completed on 16 July 2026 for a fair value consideration of EUR 97.8 million (approx Rs. 10,797.6 million) (comprising cash consideration of Rs. 8,778.3 million and deferred consideration of Rs. 2,019.3 million), subject to adjustments in accordance with the terms of the SPA. Accordingly, Occlutech became a subsidiary of the Group with effect from the acquisition date, and its financial results have been consolidated from 16 July 2026. Consequently, the results for the current period are not comparable with those of the corresponding previous periods. The acquisition has been accounted for in accordance with Ind AS 103, Business Combinations. Based on the provisional Purchase Price Allocation (PPA), identifiable assets and liabilities acquired amounted to Rs. 16,047.8 million and Rs. 9,208.6 million (including deferred tax liability of Rs. 1,724.0 million) respectively. The acquisition resulted in recognition of goodwill of Rs. 7,036.0 million. The PPA will be finalised within the measurement period permitted under Ind AS 103, and any resulting adjustments will be recognized retrospectively from the acquisition date.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 3,15,412.00
Capital work-in-progress 16,079.00
Investment property 0.00
Goodwill 1,22,102.00
Other intangible assets 1,36,076.00
Intangible assets under development 14,219.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 3,369.00
Non-current financial assets
Non-current investments 1,18,344.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 72,498.00
Total of other non-current financial assets 72,498.00
Total non-current financial assets 1,90,842.00
Deferred tax assets (net) 1,74,718.00
Other non-current assets
1 Other non-current assets 26,564.00
Total of other non-current assets 26,564.00
Total non-current assets 9,99,381.00
2 Current assets
Inventories 3,52,527.00
Current financial asset
Current investments 85,597.00
Trade receivables, current 3,37,005.00
Cash and cash equivalents 40,843.00
Bank balance other than cash and cash equivalents 20,910.00
Loans, current 909.00
Other current financial assets
Total of other current financial assets 3,57,892.00
Total current financial assets 8,43,156.00
Current tax assets (net) 8,369.00
Other current assets
1 Other current assets 1,02,531.00
Total of other current assets 1,02,531.00
Total current assets 13,06,583.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 23,05,964.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 2,391.00
Other equity 14,84,130.00
Total equity attributable to owners of parent 14,86,521.00
Non controlling interest 82,379.00
Total equity 15,68,900.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1,03,346.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 96,687.00
Total of other non-current financial liabilities 96,687.00
Total non-current financial liabilities 2,00,033.00
Provisions, non-current 44,164.00
Deferred tax liabilities (net) 20,339.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 1,619.00
Total of other non-current liabilities 1,619.00
Total non-current liabilities 2,66,155.00
Current liabilities
Current financial liabilities
Borrowings, current 82,960.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 13,137.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,97,213.00
Total Trade payable 2,10,350.00
Other current financial liabilities
1 Other current financial liabilities 1,00,545.00
Total of other current financial liabilities 1,00,545.00
Total current financial liabilities 3,93,855.00
Other current liabilities 34,989.00
1 Other current liabilities 34,989.00
Total of other current liabilities 34,989.00
Provisions, current 21,959.00
Current tax liabilities (Net) 20,106.00
Deferred government grants, Current 0.00
Total current liabilities 4,70,909.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 7,37,064.00
Total equity and liabilites 23,05,964.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 4,34,792.00 8,00,124.00
2 Biotech 12,979.00 24,965.00
3 MedTech 13,314.00 14,079.00
Total Segment Revenue 4,61,085.00 8,39,168.00
Less: Inter segment revenue 5,886.00 9,954.00
Revenue from operations 4,55,199.00 8,29,214.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 1,05,188.00 1,82,127.00
2 Biotech (11,414.00) (20,542.00)
3 MedTech (4,963.00) (6,188.00)
Total Profit before tax 88,811.00 1,55,397.00
i. Finance cost 5,767.00 10,429.00
ii. Other Unallocable Expenditure net off Unallocable income (13,421.00) (28,696.00)
Profit before tax 96,465.00 1,73,664.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 10,18,895.00 10,18,895.00
2 Biotech 1,68,840.00 1,68,840.00
3 MedTech 2,48,634.00 2,48,634.00
Total Segment Asset 14,36,369.00 14,36,369.00
Un-allocable Assets 8,69,596.00 8,69,596.00
Net Segment Asset 23,05,965.00 23,05,965.00
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 4,15,355.00 4,15,355.00
2 Biotech 61,649.00 61,649.00
3 MedTech 33,307.00 33,307.00
Total Segment Liabilities 5,10,311.00 5,10,311.00
Un-allocable Liabilities 2,26,753.00 2,26,753.00
Net Segment Liabilities 7,37,064.00 7,37,064.00
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) Pursuant to the acquisition of a controlling interest in Occlutech Holding AG in July 2026, the Group reassessed its reportable operating segments following changes in the information being reviewed by the Chief Operating Decision Maker (CODM). Based on the revised internal reporting, the Group has identified Pharmaceuticals, Biotech and MedTech as its reportable operating segments. Following the change in the composition of the Group’s reportable operating segments, comparative segment information for the prior periods presented has been prepared on the basis of the current reportable segment structure to facilitate comparability. Accordingly, segment information has been presented in accordance with the requirements of Ind AS 108. 'The Group’s treasury operations are managed centrally. Accordingly, cash and bank balances, investments, bank deposits, deposits with financial institutions, borrowings from banks and financial institutions, other related assets and liabilities and resulting income/expense have been presented as unallocated assets, liabilities, income and expense. Further, all tax assets and liabilities have also been presented as unallocated assets and liabilities.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of defined benefit plans (290.00) (544.00)
Total Amount of items that will not be reclassified to profit and loss (290.00) (544.00)
2 Income tax relating to items that will not be reclassified to profit or loss (54.00) (138.00)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 923.00 465.00
5 Total Other comprehensive income (1,159.00) (871.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,77,164.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 10,429.00
Adjustments for decrease (increase) in inventories (7,253.00)
Adjustments for decrease (increase) in trade receivables, current (33,391.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (10,806.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,679.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 23,727.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 180.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 863.00
Adjustments for dividend income 7.00
Adjustments for interest income 21,605.00
Adjustments for share-based payments (72.00)
Adjustments for fair value losses (gains) (310.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (1,374.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (35,940.00)
Net cash flows from (used in) operations 1,41,224.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 36,766.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 1,04,458.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 80,804.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 1,359.00
Purchase of property, plant and equipment 32,089.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 4,17,942.00
Purchase of other long-term assets 3,61,406.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 7.00
Interest received 17,160.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (37,831.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 94,722.00
Repayments of borrowings 1,23,648.00
Payments of lease liabilities 4,449.00
Dividends paid 12,482.00
Interest paid 8,775.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 10,240.00
Net cash flows from (used in) financing activities (44,392.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 22,235.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 282.00
Net increase (decrease) in cash and cash equivalents 22,517.00
Cash and cash equivalents cash flow statement at beginning of period (34,214.00)
Cash and cash equivalents cash flow statement at end of period (11,697.00)